Abstract
Abstract.Background: The effect of serum lycopene on the progression of cardiovascular diseases (CVDs) and their longevity remains a controversial topic. The purpose of this study was to evaluate the associations of different isomeric forms of serum lycopene with CVD and all-cause mortality in the American population. Methods: The National Health and Nutrition Examination Survey (NHANES) is a large population survey to investigate public health in the US. We analyzed data from 2003–2006 linked with mortality data obtained in 2015. Cox proportional hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated to assess the risk of CVD and all-cause mortality caused by serum lycopene. Results: Among 7452 participants (aged 20–85 years, 46.7% male), 298 died from CVDs among the total 1213 deaths during a median follow-up of 10.7 years. Serum lycopene is a protective factor for all-cause and CVD mortality. In multivariable-adjusted models, the hazard ratio (with 95% confidence intervals) associated with Q4 compared to Q1 of serum total-lycopene, trans-lycopene and cis-lycopene was 0.49 (0.38,0.63), 0.49 (0.39,0.63) and 0.55 (0.43,0.70) for all-cause mortality (Ptrend<0.05), and was 0.53 (0.32,0.96), 0.48 (0.32,0.72) and 0.63 (0.41,0.97) for CVD mortality (Ptrend<0.05). The subgroup analyses showed that different isomeric forms of lycopene showed varied associations with CVD and all-cause mortality based on age, drinking status, history of hypertension and diabetes. Conclusions: Serum lycopene concentration was significantly associated with the risk of CVD and all-cause mortality. Cis-lycopene had a U-shaped relationship with mortality, while trans-lycopene had an inverse relationship with it.
References
1 . Cardiovascular diseases (CVDs): fact sheets [Internet]. World Health Organization; 2021 Jun 11; [cited 2021 Aug 22]. Available from: https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
2 Modifiable risk factors for cardiovascular disease in Korea and Japan. Korean Circ J. 2021;51(8):643–55.
3 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596–e646.
4 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Europ Heart J. 2016;37(29):2315–81.
5 . Lycopene: chemistry, biology, and implications for human health and disease. Nutr Rev. 1998;56:35–51.
6 A dose-response study on the effects of purified lycopene supplementation on biomarkers of oxidative stress. J Am Coll Nutr. 2008;27(2):267–73.
7 Lycopene: a natural arsenal in the war against oxidative stress and cardiovascular diseases. Antioxidants (Basel). 2022;11(2):232.
8 Low-serum carotenoid concentrations and carotenoid interactions predict mortality in US adults: the Third National Health and Nutrition Examination Survey. Nutr Res. 2011;31(3):178–89.
9 . Can diet prevent urological cancers? An update on carotenoids as chemopreventive agents. Nutrients. 2022;14:1367.
10 . How do nutritional and hormonal status modify the bioavailability, uptake, and distribution of different isomers of lycopene? J Nutr. 2005;135:2046S–7S.
11 . Trolox equivalent antioxidant capacity of different geometrical isomers of α-carotene, β-carotene, lycopene, and zeaxanthin. J Agric Food Chem. 2002;50(1):221–6.
12 . Relationship of lycopene intake and consumption of tomato products to incident CVD. Br J Nutr. 2013;110:545–51.
13 . Dietary and circulating lycopene and stroke risk: a meta-analysis of prospective studies. Sci Rep. 2014;4:5031.
14 . Dietary antioxidants, circulating antioxidant concentrations, total antioxidant capacity, and risk of all-Cause mortality: A systematic review and dose-response meta-analysis of prospective observational studies. Adv Nutr. 2018;9:701–16.
15 . Effects of oral lycopene supplementation on vascular function in patients with cardiovascular disease and healthy volunteers: a randomised controlled trial. PLoS One. 2014;9:e99070.
16 . Cardiovascular disease mortality and serum carotenoid levels: a Japanese population-based follow-up study. J Epidemiol. 2006;16:154–60.
17 . Associations between antioxidants and all-cause mortality among US adults with obstructive lung function. Br J Nutr. 2014;112:1662–73.
18 . Serum lycopene is inversely associated with long-term all-cause mortality in individuals with rheumatoid arthritis: Result from the NHANES III. Eur J Integr Med. 2016;8:213–8.
19 . Higher levels of serum lycopene are associated with reduced mortality in individuals with metabolic syndrome. Nutr Res. 2016;36:402–7.
20 . Plasma lycopene, other carotenoids, and retinol and the risk of cardiovascular disease in women. Am J Clin Nutr. 2004;79:47–53.
21 Effect of lycopene supplementation on cardiovascular parameters and markers of inflammation and oxidation in patients with coronary vascular disease. Food Sci Nutr. 2018;6:1770–7.
22 . Natural antioxidants from tomato extract reduce blood pressure in patients with grade-1 hypertension: a double-blind, placebo-controlled pilot study. Am Heart J. 2006;151:160.
23 . Lycopene regulation of cholesterol synthesis and efflux in human macrophages. J Nutr Biochem. 2011;22:971–8.
24 5-cis-, Trans- and Total Lycopene Plasma Concentrations Inversely Relate to Atherosclerotic Plaque Burden in Newly Diagnosed Type 2 Diabetes Subjects. Nutrients. 2020;12:1696.
25 Tomato (Lycopersiconesculentum) or lycopene supplementation attenuates ventricular remodeling after myocardial infarction through different mechanistic pathways. J Nutr Biochem. 2017;46:117–24.
26 National health and nutrition examination survey: analytic guidelines, 1999–2010. Vital Health Stat. 2013;2:1–24.
27 . Laboratory procedures used for the third National Health and Nutrition Examination Survey (NHANES III). Available from: https://www.cdc.gov/nchs/data/nhanes/nhanes3/cdrom/nchs/manuals/labman.pdf.
28 . Assessment of the US diet in national nutrition surveys: national collaborative efforts and NHANES. Am J Clin Nutr. 1994;59:164S–7S.
29 . Healthy Eating Index-2010 and food groups consumed by US adults who meet or exceed fiber intake recommendations NHANES 2001–2010. Food Nutr Res. 2016;60:29977.
30 Associations of healthy lifestyle and socioeconomic status with mortality and incident cardiovascular disease: two prospective cohort studies. BMJ. 2021;373:n604.
31 . Lycopene and vascular health. Front Pharmacol. 2018;9:521.
32 . Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst. 1999;91:317–31.
33 Potential role of lycopene in the treatment of hepatitis C and prevention of hepatocellular carcinoma. Nutr Cancer. 2008;60:729–35.
34 Lycopene inhibits smoke-induced chronic obstructive pulmonary disease and lung carcinogenesis by modulating reverse cholesterol transport in ferrets. Cancer Prev Res (Phila). 2019;12:421–32.
35 From carotenoid intake to carotenoid blood and tissue concentrations – implications for dietary intake recommendations. Nutr Rev. 2021;79:544–73.
36 . Association between diabetes mellitus and the risk for major cardiovascular outcomes and all-cause mortality in women compared with men: a meta-analysis of prospective cohort studies. BMJ Open. 2019;9.
37 . Diabetes mellitus and oxidative stress – a concise review. Saudi Pharm J. 2016;24:547–553.
38 . Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018;34:575–84.
39 . Mechanisms of dysfunction in the aging vasculature and role in age-related disease. Circ Res. 2018;123:825–48.
40 . All-cause and cause-specific mortality in Scotland 1981–2011 by age, gender and deprivation: a population-based study. Eur J Public Health. 2019;29:647–55.
41 . The role of oxidative stress during inflammatory processes. Biol Chem. 2014;395:203–30.
42 . Potential inhibitory effect of lycopene on prostate cancer. Biomed Pharmacother. 2020;129:110459.